Elena Ridloff Sells 3,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Elena Ridloff sold 3,000 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $87.00, for a total value of $261,000.00. Following the completion of the transaction, the director directly owned 3,000 shares in the company, valued at $261,000. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Elena Ridloff also recently made the following trade(s):

• On Tuesday, March 31st, Elena Ridloff sold 7,400 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.37, for a total value of $631,738.00.
• On Wednesday, April 1st, Elena Ridloff sold 4,600 shares of Kymera Therapeutics stock. The shares were sold at an average price of $85.42, for a total value of $392,932.00.

Kymera Therapeutics Price Performance

NASDAQ:KYMR opened at $83.55 on Wednesday. The firm has a market capitalization of $6.87 billion, a PE ratio of -23.40 and a beta of 2.06. The business’s fifty day moving average price is $83.79 and its 200 day moving average price is $77.53. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.18. The firm had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.Kymera Therapeutics’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.82) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.34 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC raised its holdings in Kymera Therapeutics by 382.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares in the last quarter. Larson Financial Group LLC increased its holdings in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares in the last quarter. Osaic Holdings Inc. increased its holdings in Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares in the last quarter. Bessemer Group Inc. increased its holdings in Kymera Therapeutics by 652.0% in the third quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after buying an additional 815 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in Kymera Therapeutics in the fourth quarter valued at about $63,000.

Analysts Set New Price Targets

KYMR has been the subject of several research analyst reports. Jefferies Financial Group initiated coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 price objective for the company. UBS Group upped their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a research note on Tuesday, March 3rd. Canaccord Genuity Group initiated coverage on shares of Kymera Therapeutics in a research note on Wednesday, May 6th. They issued a “buy” rating and a $106.00 price objective for the company. Stephens upped their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $118.10.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.